La enfermedad de injerto contra huésped (EICH) es una complicación común después de un trasplante que utiliza células de un donante (trasplante alogénico). Hay dos tipos diferentes de EICH que difieren en los órganos que afectan y en el momento en que se desarrollan normalmente. Esta presentación analiza las causas de la EICH, cómo afecta a varios órganos y las opciones de tratamiento.

Acute myeloid leukemia (AML) is a blood cancer that has been historically challenging to treat. It often requires a bone marrow or stem cell transplant that can be curative but brings significant risks and side effects. However, new drugs and clinical trials have expanded treatment options and moderated side effects for many patients.

CAR T cell therapy is a new type of therapy for patients with multiple myeloma. It is currently available for patients who have relapsed after four or more rounds prior therapy. This presentation describes CAR T cell and related therapies as well as new drugs in the pipeline to treat patients with multiple myeloma

Anxiety and depression are common among cancer patients and survivors. Acceptance and commitment therapy is an effective tool for these problems. This presentation discusses the mental health challenges of transplant and GVHD patients and how this therapy can help them.

Sickle cell disease disproportionately affects African Americans. However, stem cell transplants and gene therapy offer promising treatment options. This presentation describes these treatments, their outcomes, and which treatments are appropriate for which patients.

Occupational therapists can help transplant recipients manage their fatigue, and redesign their lifestyle to improve quality of life, while recovering transplant and side effects such as graft-versus-host disease (GVHD).

Puntos clave: 19:17 Tener la enfermedad de injerto contra huésped es un factor de riesgo adicional de COVID-19. 23:31 Los tratamientos para los casos leves se manejan mejor en casa

It is now my pleasure to introduce your host, Susan Stewart. Susan Stewart ( 00:00:05): Introductions Thank you very much, and welcome to the COVID-19 Winter Update: What Transplant Recipients

Chronic ocular graft-versus-host disease (GVHD) affects more than 50% of patients who have chronic GVHD. A variety of therapies are available and should be approached in a step-ladder manner.

The immune system fights both infection and cancer. When cancer cells evade the immune system, the patient's T-cells, which are part of the immune system, can be genetically engineered to fight the cancer cells. This is called CAR T cell therapy.